Abstract Background  The existing body of literature is deficient in the most recent data regarding the global perspective of dengue fever and its associated health inequities.Our aim is to assess the global burden of dengue fever and its health inequities from 1990 to 2021. Methods We utilized the Global Burden of Disease (GBD) database for epidemiological trends, demographic analysis, and epidemiological decomposition. Cross-national inequality and predictive modeling for the global dengue burden up to 2051 were also performed. Results Globally, dengue fever incidence, prevalence, DALYs, and mortality showed increasing trends with significant international disparities. From 1990 to 2021, ASR for incidence and prevalence rose by 1.83% (95% CI: 1.58%-2.08%), and for DALYs and mortality by 1.33% (95% CI: 1.10%-1.57%) and 1.70% (95% CI: 1.45%-1.94%), respectively. Age-period-cohort-model analysis revealed a positive correlation between dengue fever incidence and age, with mortality sharply increasing in those over 80. Decomposition of dengue fever DALYs burden showed population growth as the main contributor to the global burden, with varying impacts across SDI quintiles. Inequalities in dengue fever burden related to SDI persisted, shifting benefits from impoverished to affluent populations. BAPC model projections suggest stabilization of incidence and prevalence ASRs, with declining DALYs and mortality ASRs,     particularly for females. Conclusion This study elucidates the changes in the burden of dengue fever against the backdrop of a burgeoning global population, severe aging, and pronounced health inequities across nations, quantifying these alterations and forecasting the trends in the disease burden over the next three decades. Concurrently, the research proposes effective measures for various countries and regions to mitigate health inequities associated with dengue fever and to reduce the associated disease burden.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files.